Teva Pharmaceuticals (NYSE: TEVA) released its full-year 2013 forecast, which missed top-line estimates by 4% and bottom-line estimates by 11%. The markets haven't taken the news too badly, opening down 3% but rallying back during the day to a slight gain. In this video, Motley Fool health care analyst David Williamson tells us where these low figures may have come from and what Teva may have in store for 2013.
